Latest News

The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review

The Food and Drug Administration has agreed to review a marketing application submitted by Biogen for aducanumab, its treatment for Alzheimer’s disease, the company announced Friday.

The aducanumab application was granted priority review, which means the FDA will render an approval decision no later than March 7, 2021.

Read the rest…

Source link

Related posts

Diabetes Raises Heart Failure Risk More in Women


Magnetic ordering phenomena in the hexagonal ABX3 halides, a neutron scattering study


Smartphone and Paper Microfluidic Device for Norovirus Detection


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World